ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: FR-PO598

Characterization of Monogenic Kidney Disease in Patients over 60 Years of Age

Session Information

Category: Genetic Diseases of the Kidneys

  • 1202 Genetic Diseases of the Kidneys: Non-Cystic


  • Elhassan, Elhussein Aamir Elzein, Royal College of Surgeons in Ireland, Dublin, Ireland
  • Benson, Katherine A., Royal College of Surgeons in Ireland, Dublin, Dublin, Ireland
  • Cavalleri, Gianpiero, Royal College of Surgeons in Ireland, Dublin, Dublin, Ireland
  • Conlon, Peter J., Beaumont Hospital, Dublin, Ireland

Approximately 10% of adults with chronic kidney disease (CKD) have monogenic forms of the disease. However, the prevalence of monogenic kidney diseases in the over-60 population is not well characterized.


For genetic screening in this cohort with suspected monogenic kidney disease, excluding polycystic kidney disease, we utilized gene-panel and exome sequencing. The purpose of this study was to assess the diagnostic yield of clinically validated disease-causing variants and to compare the clinical characteristics of solved and unsolved cohorts.


Genetic testing was performed for 113 adults (n= 93 families) with a median age at recruitment of 69 years (IQR: 64 - 73). 83.3% participants reported a family history of CKD and 52.2% were females. At last follow up, 84 (75.7%) individuals progressed to kidney failure at a median age of 57 years [IQR: 41.5 – 65]. We were able to demonstrate likely-pathogenic/pathogenic variant in 37/113 (32.7%), encompassing 13 distinct monogenic entities. Disease-causing variants in three phenotypes accounted for up to 76% of solved cases. These included MUC1 (n=6), UMOD (n=3), HNF1B (n=5) and DNAJB11 (n=1) associated with tubulointerstitial kidney disease; COL4A5 (n=4) and monoallelic COL4A3 (n=4) associated with Alport–related kidney disease; and INF2 (n=5) associated with focal segmental glomerulosclerosis. We identified disease-causing variants in the CLCN5 gene associated with Dent disease type 1 in an additional 3 (2.6%) individuals. In 32% (n=8) of the 25 patients referred with a priori diagnosis of CKD of undetermined cause were found to have a known monogenic cause. There was no difference in age at initial presentation [45.4 vs. 46 years; p = 0.863] and age at kidney failure [52.8 vs. 52.8 years; p = 0.747] between individuals with monogenic disease and those without. A family history of CKD was an independent predictor of a genetic diagnosis [odds ratio: 5; 95% CI: 1.1 - 23.3, p = 0.040], with a higher proportion of solved cases than unsolved cases [94.4% vs. 77.7%, p = 0.02].


We estimated that about a third of this cohort over 60 years old with suspected inherited CKD would have a monogenic nephropathy. Awareness of monogenic nephropathies, particularly in this population group, should permit family counselling and individualized treatment.